Abstract

Provided is an intelligent design method for a type I diabetes vaccine. The method comprises: perform computer-simulated amino-acid mutation design on an initial type I diabetes autoantigen sequence obtained from a patient with type I diabetes, and perform auxiliary rational design on the basis of an HLA-polypeptide molecule-TCR ternary complex structure. The binding affinity of an antigen to an immune molecule is optimized and improved in a targeted manner, so that significant proliferation of type I diabetes-related CD4+T lymphocytes is realized.

IPC Classes  ?

• G16B 20/50 - Mutagenesis
• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
• G16B 20/30 - Detection of binding sites or motifs
• G16C 10/00 - Computational theoretical chemistry, i.e. ICT specially adapted for theoretical aspects of quantum chemistry, molecular mechanics, molecular dynamics or the like

Abstract

Provided are a monoclonal antibody 32C7, and a preparation method therefor and the use thereof. The monoclonal antibody can effectively and specifically bind to a RBD domain of a S protein of a novel coronavirus, and in-vivo replication of the virus can be inhibited, and the production of inflammatory factors and pulmonary inflammatory infiltration can be reduced. The monoclonal antibody inhibits the novel coronavirus from entering a host cell, achieves the therapeutic effect of a novel coronavirus neutralizing antibody, and the monoclonal antibody can be used for treating or preventing respiratory system injury caused by novel coronavirus infection.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 15/13 - Immunoglobulins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 21/08 - Monoclonal antibodies
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61P 31/14 - Antivirals for RNA viruses
• C12R 1/91 - Cell lines

Abstract

Provided are a monoclonal antibody 35B5, a preparation method therefor, and a use thereof. By preparing a neutralizing antibody 35B5 against the RBD domain of a novel coronavirus, it is verified in vitro, by means of surface plasmon resonance detection, that the antibody 35B5 can effectively bind to the RBD domain of the S protein of the novel coronavirus, the neutralizing ability of the antibody 35B5 is verified by transfecting a mouse infection model, and the inhibitory effect of the neutralizing antibody 35B5 on lung virus titer and related inflammatory factors after the novel coronavirus infection is determined. The results show that the neutralizing antibody can significantly inhibit the replication of the novel coronavirus in vivo and reduce the production of inflammatory factors and the inflammatory infiltration of the lungs. The monoclonal antibody 35B5 inhibits the entry of the novel coronavirus into host cells, achieves the therapeutic effect of a neutralizing antibody for the novel coronavirus, and is effective for treating or preventing respiratory system damage caused by infection by the novel coronavirus.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 15/13 - Immunoglobulins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12R 1/91 - Cell lines
• C12P 21/08 - Monoclonal antibodies
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61P 31/14 - Antivirals for RNA viruses